PMID- 26577038
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20220129
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 5
DP  - 2015 Nov 18
TI  - Sodium channel-inhibiting drugs and survival of breast, colon and prostate 
      cancer: a population-based study.
PG  - 16758
LID - 10.1038/srep16758 [doi]
LID - 16758
AB  - Metastasis is the leading cause of cancer-related deaths. Voltage-gated sodium 
      channels (VGSCs) regulate invasion and metastasis. Several VGSC-inhibiting drugs 
      reduce metastasis in murine cancer models. We aimed to test the hypothesis that 
      patients taking VGSC-inhibiting drugs who developed cancer live longer than those 
      not taking these drugs. A cohort study was performed on primary care data from 
      the QResearch database, including patients with breast, bowel or prostate cancer. 
      Cox proportional hazards regression was used to compare the survival from cancer 
      diagnosis of patients taking VGSC-inhibiting drugs with those not exposed to 
      these drugs. Median time to death was 9.7 years in the exposed group and 18.4 
      years in the unexposed group, and exposure to these medications significantly 
      increased mortality. Thus, exposure to VGSC-inhibiting drugs associates with 
      reduced survival in breast, bowel and prostate cancer patients. This finding is 
      not consistent with the preclinical data. Despite the strengths of this study 
      including the large sample size, the study is limited by missing information on 
      potentially important confounders such as cancer stage, co-morbidities and cause 
      of death. Further research, which is able to account for these confounding 
      issues, is needed to investigate the relationship between VGSC-inhibiting drugs 
      and cancer survival.
FAU - Fairhurst, Caroline
AU  - Fairhurst C
AD  - Department of Health Sciences, University of York, York, UK, YO10 5DD.
FAU - Watt, Ian
AU  - Watt I
AD  - Department of Health Sciences, University of York, York, UK, YO10 5DD.
AD  - Hull York Medical School, York, UK, YO10 5DD.
FAU - Martin, Fabiola
AU  - Martin F
AD  - Hull York Medical School, York, UK, YO10 5DD.
AD  - Department of Biology, University of York, York, UK, YO10 5DD.
FAU - Bland, Martin
AU  - Bland M
AD  - Department of Health Sciences, University of York, York, UK, YO10 5DD.
FAU - Brackenbury, William J
AU  - Brackenbury WJ
AD  - Department of Biology, University of York, York, UK, YO10 5DD.
LA  - eng
GR  - G1000508/MRC_/Medical Research Council/United Kingdom
GR  - 097829/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151118
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Voltage-Gated Sodium Channel Blockers)
RN  - 0 (Voltage-Gated Sodium Channels)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/epidemiology/*metabolism/*mortality
MH  - Colonic Neoplasms/epidemiology/*metabolism/*mortality
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Population Surveillance
MH  - Prognosis
MH  - Prostatic Neoplasms/epidemiology/*metabolism/*mortality
MH  - Risk Factors
MH  - Voltage-Gated Sodium Channel Blockers/*pharmacology/therapeutic use
MH  - Voltage-Gated Sodium Channels/*metabolism
PMC - PMC4649474
EDAT- 2015/11/19 06:00
MHDA- 2016/09/16 06:00
PMCR- 2015/11/18
CRDT- 2015/11/19 06:00
PHST- 2015/07/27 00:00 [received]
PHST- 2015/10/20 00:00 [accepted]
PHST- 2015/11/19 06:00 [entrez]
PHST- 2015/11/19 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
PHST- 2015/11/18 00:00 [pmc-release]
AID - srep16758 [pii]
AID - 10.1038/srep16758 [doi]
PST - epublish
SO  - Sci Rep. 2015 Nov 18;5:16758. doi: 10.1038/srep16758.